Lille (France), Boston (Massachusetts, United States), April 29th, 2013 – GENFIT (Alternext: ALGFT; ISIN:
FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing
on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces
the conversions into shares of 30 bonds OCA2012-2 in keeping with the convertible loan contract signed with
the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd.
In keeping with the 1st and 2nd resolutions of the Extraordinary Shareholders’ Meeting held on December 18th,
2012 and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting
for and on behalf of YA Global Master SPV Ltd (“the Bondholder”), the Bondholder requested one first
conversion on April 25th, and then two other conversions on April 26th, 2013 for a total value of €300,000.
The first conversion on April 25th of 10 bonds OCA2012-2 into 17,714 new shares was performed at a
conversion rate of €5.64, issue premium included, equivalent to 95% of the arithmetic mean of the volumeweighted
average GENFIT share price for the five trading days (April 18th, 2013- April 24th, 2013) prior to the
The two other conversions on April 26th of a total of 20 bonds OCA2012-2 into 35,270 new shares was
performed at a conversion rate of €5.67, issue premium included, equivalent to 95% of the arithmetic mean of
the volume-weighted average GENFIT share price for the five trading days (April 19th, 2013- April 25th, 2013)
prior to the conversion requests.
As a result of these reserved share issues:
- The social capital of GENFIT has increased from €5,086,105.75 to €5,099,351.75;
- The number of shares representing the social capital of GENFIT has increased by 52,984, from
20,344,423 to 20,397,407 shares;
- The amount of the 7th installment of the bond loan agreement that remains to be converted is
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in
therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia,
inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive
solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in
partnership with leading pharmaceutical companies, including Sanofi, to address these major public health
concerns and their unmet medical needs.
GENFIT’s research programs have resulted in the creation of a rich and diversified pipeline of drug candidates
at different stages of development, including GENFIT’s lead proprietary compound, GFT505, that is currently in
With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees.
GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN:
Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000
MILESTONES – Press Relations
Ph. +33 1 7544 8740 / +336 8788 4726 – email@example.com